Table 2. Treatment outcome.
| Artemether-lumefantrine | Dihydroartemisinin-piperaquine | Weighted odds ratio | |
|---|---|---|---|
| Number | 155 | 157 | |
| ACPR | 128 | 136 | |
| Per protocol ACPR | 95% | 100% | 0.22 (95% CI 0–0.68)*, p = 0.022 |
| Early treatment failure | 4 | 0 | |
| Late clinical failure | 3 | 0 | |
| Modified intention to treat ACPR | 94% | 97% | 0.43 (95% CI, 0.10–1.56), p = 0.15 |
| Early treatment failure | 6 | 2 | |
| Late clinical failure | 3 | 0 | |
| New infection | 0 | 2 | |
| Withdrawal of consent | 3 | 5 | |
| Lost to follow up | 15 | 12 |
ACPR Adequate clinical and parasitological response
*There were two treatment failures in both the DP and AL group on day 0 that were treated as wrong inclusions in the per protocol analysis.
In the modified intention to treat analysis treatment failures on day 0 and new infections were considered as treatment failures. Withdrawal of consent and loss to follow up were censored in the per protocol and intention to treat analyses.